SCHEMBL6270779

SCHEMBL6270779

CCCC(C)COc1c(O)c2ccc(OCCO)cc2oc1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP1LC3B Q9GZQ8 1/20 0.43
MAP1LC3A Q9H492 1/20 0.43
KDM4E B2RXH2 3/20 0.43
ALDH1A1 P00352 3/20 0.43
HPGD P15428 3/20 0.43
TSHR P16473 2/20 0.43
HSD17B10 Q99714 2/20 0.43
MAPT P10636 1/20 0.43
MAPK1 P28482 1/20 0.43
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NQO1 P15559 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA9 Q16790 1/20 0.41
GAA P10253 1/20 0.41
XDH P47989 1/20 0.41
ALDH2 P05091 2/20 0.40
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6275587 0.95 MAP1LC3B (0.45) MAP1LC3BMAP1LC3AKDM4EALDH1A1HPGD
SCHEMBL6274541 0.92 NQO1 (0.41) MAP1LC3BMAP1LC3AKDM4EALDH1A1HPGD
SCHEMBL6274712 0.87 NQO1 (0.41) MAP1LC3BMAP1LC3AKDM4EALDH1A1HPGD
SCHEMBL6275984 0.87 AKR1C3 (0.52) KDM4EALDH1A1HPGDHSD17B10MAPT
SCHEMBL6274722 0.86 MAP1LC3B (0.51) MAP1LC3BMAP1LC3AKDM4EALDH1A1HPGD
SCHEMBL6276865 0.86 KDM4E (0.55) MAP1LC3BMAP1LC3AKDM4EALDH1A1HPGD
SCHEMBL6274233 0.85 SIRT1 (0.43) MAP1LC3BMAP1LC3AKDM4EALDH1A1HPGD
SCHEMBL6272795 0.84 ALDH1A1 (0.53) MAP1LC3BMAP1LC3AKDM4EALDH1A1HPGD
SCHEMBL27582284 0.84 NQO1 (0.50) MAP1LC3BMAP1LC3AKDM4EALDH1A1HPGD
SCHEMBL6277695 0.84 ALDH2 (0.52) MAP1LC3BMAP1LC3AKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1273578-B1 Benzopyran derivatives and antiallergic agent containing the same DAINIPPON INK & CHEMICALS (JP) 2005-02-23 EP disclosed
US-6670391-B2 For inhibiting both immediate and delayed type allergic reactions; side effect reduction DAINIPPON INK AND CHEMICALS, INC. (JP) 2003-12-30 US disclosed
US-20030096860-A1 Benzopyran derivative and antiallergic agent DAINIPPON INK AND CHEMICALS, INC. (JP) 2003-05-22 US disclosed
EP-1273578-A1 Benzopyran derivatives and antiallergic agent containing the same DAINIPPON INK AND CHEMICALS, INC. (JP) 2003-01-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030096860-A1 Benzopyran derivative and antiallergic agent HRH2, HRH1, HRH4 MAP1LC3B 4772/4885MAP1LC3A 4614/4885KDM4E 965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.